PTPN11 (SHP2), a critical node in receptor tyrosine kinase (RTK) signaling, is consistently upregulated in ovarian cancer and promotes tumor progression via the PI3K-AKT and ERK-MAPK pathways (Fedele et al., 2018; Cao et al., 2022). This evidence concerns the gene AKT1 and ovarian carcinoma.